Establishing Meaningful Change Thresholds in Patient-Reported Outcomes among Patients with ALK-positive NSCLC in ALTA-1L Trial.

Jennifer L Beaumont,Huamao M Lin,Erin Goodman,Hailin Yu, Ashley Geiger,Stacie Hudgens

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research（2023）

引用 0|浏览1

暂无评分

摘要

This study derived MCTs for EORTC QLQ-C30 and QLQ-LC13 domains that may be applied in future studies and again demonstrated the superiority of brigatinib over crizotinib in HRQoL outcomes in NSCLC patients.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要